Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,052
archived clinical trials in
Nephrology

Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
Tennova Healthcare - Turkey Creek Medical Center
mi
from
Knoxville, TN
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
Tennova Healthcare - Turkey Creek Medical Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
The Methodist Hospital of Research
mi
from
Houston, TX
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
The Methodist Hospital of Research
mi
from
Houston, TX
Click here to add this to my saved trials
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
Cardiovascular Associates of East Texas, P.A.
mi
from
Tyler, TX
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
Cardiovascular Associates of East Texas, P.A.
mi
from
Tyler, TX
Click here to add this to my saved trials
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
Charleston Area Medical Center
mi
from
Charleston, WV
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
Charleston Area Medical Center
mi
from
Charleston, WV
Click here to add this to my saved trials
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
York Hospital
mi
from
York, PA
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
York Hospital
mi
from
York, PA
Click here to add this to my saved trials
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated:  5/18/2016
Cardiology Center Leipzig Ltd.
mi
from
Leipzig,
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial
Status: Enrolling
Updated: 5/18/2016
Cardiology Center Leipzig Ltd.
mi
from
Leipzig,
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
Mayo Clinic Scottsdale
mi
from
Phoenix, AZ
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
Mayo Clinic Scottsdale
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
IU Health Physicians Urology
mi
from
Indianapolis, IN
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
IU Health Physicians Urology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
Johns Hopkins
mi
from
Baltimore, MD
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
Duke University
mi
from
Durham, NC
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
University of Wisconsin
mi
from
Madison, WI
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
Northwestern University
mi
from
Chicago, IL
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated:  6/28/2016
University of British Columbia
mi
from
Vancouver,
Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy
Status: Enrolling
Updated: 6/28/2016
University of British Columbia
mi
from
Vancouver,
Click here to add this to my saved trials
Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy
Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy
Status: Enrolling
Updated:  7/25/2016
California Pacific Medical Center
mi
from
San Francisco, CA
Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy
Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy
Status: Enrolling
Updated: 7/25/2016
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated:  8/11/2016
Shionogi Research Site
mi
from
Jackson, MS
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated: 8/11/2016
Shionogi Research Site
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated:  8/11/2016
Shionogi Research Site
mi
from
Lima, OH
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated: 8/11/2016
Shionogi Research Site
mi
from
Lima, OH
Click here to add this to my saved trials
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated:  8/11/2016
Shionogi Research Site
mi
from
Pleven,
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated: 8/11/2016
Shionogi Research Site
mi
from
Pleven,
Click here to add this to my saved trials
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
Oral Hydration and Alkalinization is Non-Inferior to Intravenous Therapy for Prevention of Contrast Induced Nephropathy in Patients With Chronic Kidney Disease.
Status: Enrolling
Updated:  11/29/2016
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
Oral Hydration and Alkalinization is Non-Inferior to Intravenous Therapy for Prevention of Contrast Induced Nephropathy in Patients With Chronic Kidney Disease.
Status: Enrolling
Updated: 11/29/2016
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Los Angeles, CA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Stanford, CA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
New Orleans, LA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Ann Arbor, MI
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Cleveland, OH
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Columbus, OH
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Philadelphia, PA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Edmonton,
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
FloSeal Tubeless Exit Versus Cope Loop Nephrostomy Versus Fascial Stitch Following Percutaneous Nephrolithotripsy
Prospective Randomized Trial of Floseal Tubeless Exit vs. Cope Loop Nephrostomy vs. Fascial Stitch Following Percutaneous Nephrolithotripsy
Status: Enrolling
Updated:  12/12/2016
University of California, Irvine Medical Center-Department of Urology
mi
from
Orange, CA
FloSeal Tubeless Exit Versus Cope Loop Nephrostomy Versus Fascial Stitch Following Percutaneous Nephrolithotripsy
Prospective Randomized Trial of Floseal Tubeless Exit vs. Cope Loop Nephrostomy vs. Fascial Stitch Following Percutaneous Nephrolithotripsy
Status: Enrolling
Updated: 12/12/2016
University of California, Irvine Medical Center-Department of Urology
mi
from
Orange, CA
Click here to add this to my saved trials
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA Study
Status: Enrolling
Updated:  1/10/2017
University of California at San Francisco
mi
from
San Francisco, CA
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA Study
Status: Enrolling
Updated: 1/10/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA Study
Status: Enrolling
Updated:  1/10/2017
Columbia University Medical Center
mi
from
New York, NY
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA Study
Status: Enrolling
Updated: 1/10/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated:  1/11/2017
Stanford University Medical School
mi
from
Stanford, CA
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated: 1/11/2017
Stanford University Medical School
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated:  1/11/2017
Emory Children's Center
mi
from
Atlanta, GA
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated: 1/11/2017
Emory Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated:  1/11/2017
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
mi
from
Chicago, IL
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated: 1/11/2017
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated:  1/11/2017
Hospices Civils de Lyon
mi
from
Lyon,
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated: 1/11/2017
Hospices Civils de Lyon
mi
from
Lyon,
Click here to add this to my saved trials
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated:  1/11/2017
University of California San Diego Medical Center
mi
from
San Diego, CA
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis
Status: Enrolling
Updated: 1/11/2017
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Celecoxib (Celebrex) in the Management of Acute Renal Colic
Celecoxib in the Management of Acute Renal Colic
Status: Enrolling
Updated:  1/23/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Celecoxib (Celebrex) in the Management of Acute Renal Colic
Celecoxib in the Management of Acute Renal Colic
Status: Enrolling
Updated: 1/23/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL
Status: Enrolling
Updated:  2/16/2017
Albert Einstein Healthcare Network
mi
from
Philadelphia, PA
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL
Status: Enrolling
Updated: 2/16/2017
Albert Einstein Healthcare Network
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control
Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control: A Prospective Randomized Trial
Status: Enrolling
Updated:  4/10/2017
Boston Children's Hospital
mi
from
Boston, MA
Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control
Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control: A Prospective Randomized Trial
Status: Enrolling
Updated: 4/10/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
Status: Enrolling
Updated:  8/28/2017
New York Methodist Hospital
mi
from
New York, NY
Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
Status: Enrolling
Updated: 8/28/2017
New York Methodist Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  9/12/2017
Indiana University
mi
from
Indianapolis, IN
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 9/12/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
Status: Enrolling
Updated:  9/14/2017
Medical City Dallas Hospital
mi
from
Dallas, TX
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
Status: Enrolling
Updated: 9/14/2017
Medical City Dallas Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated:  9/21/2017
AURA-LV Site
mi
from
Los Angeles, CA
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated: 9/21/2017
AURA-LV Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated:  9/21/2017
AURA-LV Site
mi
from
Palo Alto, CA
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated: 9/21/2017
AURA-LV Site
mi
from
Palo Alto, CA
Click here to add this to my saved trials
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated:  9/21/2017
AURA-LV Site
mi
from
Gainesville, FL
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated: 9/21/2017
AURA-LV Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated:  9/21/2017
AURA-LV Site
mi
from
Miami, FL
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated: 9/21/2017
AURA-LV Site
mi
from
Miami, FL
Click here to add this to my saved trials
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated:  9/21/2017
AURA-LV Site
mi
from
Farmington Hills, MI
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated: 9/21/2017
AURA-LV Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated:  9/21/2017
AURA-LV Site
mi
from
Brooklyn, NY
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status: Enrolling
Updated: 9/21/2017
AURA-LV Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials